Characteristics and patterns of progression among 427 patients with SMM diagnosed between 2014 and 2023
| Patients’ characteristics . | (N = 427) . |
|---|---|
| Median age (y), (range) | 65 (28-88) |
| Median Hb (g/dL), (range) | 12.9 (9-16.8) |
| IgG/IgA/IgD/no heavy chain/biclonal, (%) | 71/24/0.3/3/1.5 |
| Light chain kappa/lambda/biclonal, (%) | 57/42/1 |
| Median M-spike (g/dL), (range) | 1.31 (0-4.4) |
| Serum creatinine >2 mg/dL | 2.3%∗ |
| eGFR <40 mL/min per 1.73 m2 | 6%∗ (unrelated to MG) |
| Albumin (g/dL), (range) | 4.4 (3.1-5.3) |
| B2 microglobulin (mg/L), (range) | 2.1 (0.7-20) |
| Proteinuria (grams per day), (range) | 0.005 (0-2) |
| Any FISH abnormality (n = 119) | 30% |
| Risk per 20/2/20 model | |
| Low risk (0 points) | 52% |
| Intermediate risk (1 point) | 31% |
| High risk (2-3 point) | 17% |
| Risk per IMWG scoring tool† | |
| Low risk | 49% |
| Low-intermediate | 34% |
| Intermediate | 12% |
| High | 4% |
| Patterns of disease progression | |
| All progression events | 42 (100%) |
| Soft tissue plasmacytoma | 2% (1) |
| Hypercalcemia | 0 |
| ARF | 2% (1) |
| Anemia (Hb < 10 g/dL) | 24% (11) |
| Lytic bone disease in ldWBCT | 24% (11) |
| SLiM criteria | 43% (18) |
| Patients’ characteristics . | (N = 427) . |
|---|---|
| Median age (y), (range) | 65 (28-88) |
| Median Hb (g/dL), (range) | 12.9 (9-16.8) |
| IgG/IgA/IgD/no heavy chain/biclonal, (%) | 71/24/0.3/3/1.5 |
| Light chain kappa/lambda/biclonal, (%) | 57/42/1 |
| Median M-spike (g/dL), (range) | 1.31 (0-4.4) |
| Serum creatinine >2 mg/dL | 2.3%∗ |
| eGFR <40 mL/min per 1.73 m2 | 6%∗ (unrelated to MG) |
| Albumin (g/dL), (range) | 4.4 (3.1-5.3) |
| B2 microglobulin (mg/L), (range) | 2.1 (0.7-20) |
| Proteinuria (grams per day), (range) | 0.005 (0-2) |
| Any FISH abnormality (n = 119) | 30% |
| Risk per 20/2/20 model | |
| Low risk (0 points) | 52% |
| Intermediate risk (1 point) | 31% |
| High risk (2-3 point) | 17% |
| Risk per IMWG scoring tool† | |
| Low risk | 49% |
| Low-intermediate | 34% |
| Intermediate | 12% |
| High | 4% |
| Patterns of disease progression | |
| All progression events | 42 (100%) |
| Soft tissue plasmacytoma | 2% (1) |
| Hypercalcemia | 0 |
| ARF | 2% (1) |
| Anemia (Hb < 10 g/dL) | 24% (11) |
| Lytic bone disease in ldWBCT | 24% (11) |
| SLiM criteria | 43% (18) |